SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Hence then, the article about antengene s atg 022 cldn18 2 adc granted breakthrough therapy designation for the treatment of gastric gastroesophageal junction adenocarcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma )
Also on site :
- Kendra Scott’s Dainty Pumpkin Necklace Is a Festive Finishing Touch for Fall Outfits, and It’s Under $35
- 1969 Supergroup Ballad, the ‘Greatest Song David Crosby Ever Wrote,’ Was About Joni Mitchell and Two Other Women
- Quote of the Day: Shakespeare’s Powerful Advice for Living up to Your Potential—‘Be Not Afraid of Greatness…’